Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Kohteen Moderna Inc nykyinen hinta markkinoilla on 127,07 €, ja sen 24 tunnin kaupankäyntivolyymi on 1,57B €. Omaisuuserän markkina-arvo on 50,73B € sen muututtua -1.29% viimeisen päivän aikana.
Tokenisoidun Moderna Inc kaupankäyntihinta on 127,61 €, sen tokenisoitu markkina-arvo on 652,93K € ja 24 tunnin kaupankäyntivolyymi on 1,2M €. Tokenisoitu omaisuuserä on liikkunut 16.59% viimeisen 24 tunnin aikana.